Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
NCT05401110
This study is recruiting at 5 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non Small Cell Lung Cancer
- Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Karen Reckamp, MD, MS
- Last updated on ClinicalTrials.gov
- August 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 5
- Cedars-Sinai Cancer at Beverly Hills (THO) · Beverly Hills, CA
- Cedars-Sinai Cancer at SOCC · Los Angeles, CA
- Cedars-Sinai Cancer at The Angeles Clinic and Research Institute · Los Angeles, CA
- Cedars-Sinai Medical Center · Los Angeles, CA
- Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC · Torrance, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.